Sumitomo Pharma Co.ltd. · TSE:4506
Sumitomo Pharma Co.ltd — Q1 2025 Earnings Presentation
26 slides from Sumitomo Pharma Co.ltd's earnings presentation, Jul 31, 2025
Slide 1: Conference on Q1 FY2025 Financial Results
Conference on Q1 FY2025 (April 1, 2025 to June 30, 2025) Financial Results Sumitomo Pharma Co., Ltd. July 31, 2025
Slide 2: Disclaimer Regarding Forward-looking Statements
Disclaimer Regarding Forward-looking Statements This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group’s financial results and other data. Such forward-looking statements are based on the Company’s assumptions, estimates, outlook, and ot
Slide 3: Financial Results for Q1 FY2025
Financial Results for Q1 FY2025 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 2
Slide 4: Financial Results for Q1 FY2025 (Core Basis)
Financial Results for Q1 FY2025 The forecasts for FY2025 are not revised Financial Results for Q1 FY2025 (Core Basis) Added the forecasts for 1st half of FY2025 (See P.13) Billions of JPY Q1YTD Q1YTD Change FY2025 Revenue increased primarily due FY2024 FY2025 May 13 Progress to the growth of ORGOV
Slide 5: Revenue of Major Products in North America
Financial Results for Q1 FY2025 Revenue of Major Products in North America Q1YTD Q1YTD Q1YTD Q1YTD Change FY2025 FY2024 FY2025 Change FY2024 FY2025 JPY-basis FX Results Results Results Results Value % May 13 forecasts impact Progess % Millions Billions North America Millions of USD Billions of JPY o
Slide 6: ORGOVYX Q1 Financial Results Summary
FY2025 Q1 Financial Results Summary ORGOVYX® Plan for Q1 Actual for Q1 Year-over-year YTD FY2025 YTD FY2025 comparison Volume: Exceeded Q1 plan mainly due to reduction of $226M $167M (Achievement: 210％ Medicare Part D out-of-pocket cap in Jan. 2025 135%) Price: In line with expectations Quarterl
Slide 7: MYFEMBREE Q1 Financial Results Summary
FY2025 Q1 Financial Results Summary MYFEMBREE® Plan for Q1 Actual for Q1 Year-over-year YTD FY2025 YTD FY2025 comparison Volume: In line with expectations $20M $21M (Achievement: 102% 95%) Price: In line with expectations Quarterly Demand Trends* K 50 （number of bottles, estimation） ＜Topics＞ End
Slide 8: GEMTESA Q1 Financial Results Summary
FY2025 Q1 Financial Results Summary GEMTESA® Plan for Q1 Actual for Q1 Year-over-year YTD FY2025 YTD FY2025 comparison Volume: Achieved Q1 plan due to the better-than- $147M 189％ expected acquisition of shares in β3 market $138M (Achievement: 107%) Price: In line with expectations Quarterly Dema
Slide 9: Revenue of Major Products in Japan
Financial Results for Q1 FY2025 Revenue of Major Products in Japan Billions of JPY Q1YTD Q1YTD Change FY2025 FY2024 FY2025 May 13 Progress Results Results Value ％ forecasts % Japan LATUDA® 3.4 3.5 0.1 3.1 13.5 25.7 TWYMEEG® 1.7 2.4 0.7 40.6 11.2 21.8 TWYMEEG® revenue continued to grow METGLUCO® 1.
Slide 10: Segment Information (Core Basis)
Financial Results for Q1 FY2025 Segment Information (Core Basis) Billions of JPY North Japan Asia Total Japan America Despite the decline of gross profit due to lower revenue, Revenue 23.2 72.6 12.3 108.0 core segment profit remained flat given the SG&A Cost of sales 12.0 29.8 2.3 44.1 expense red
Slide 11: Marketing and Sales in Japan: Co-Promotion Agreement with Novo Nordisk Pharma
Marketing and Sales in Japan Conclusion of Co-Promotion Agreement with Novo Nordisk Pharma in Japan for a Type 2 Diabetes Treatment product, "Ozempic® Subcutaneous Injection 2mg" The co-promotion agreement was executed in May 2025, and joint promotional activities to medical institutions commenced
Slide 12: Strengthening Governance Structure
Strengthening Governance Structure Strengthening Corporate Governance Transition to Company with an Capital Restructuring and Audit & Supervisory Committee Asset Assignment within the Group Purpose Major Purpose Establish a structure that enables Sumitomo Pharma to commit to the Strengthen the super
Slide 13: Financial Forecasts for the First Half of FY2025
Financial Forecasts for the First Half of FY2025 © Sumitomo Pharma Co., Ltd. All Rights Reserved. 12
Slide 14: Financial Forecasts for the First Half of FY2025 (Core Basis)
Financial Forecasts for the First Half of FY2025 Financial Forecasts for the First Half of FY2025 (Core Basis) Billions of JPY FY2025 FY2025 Progress FX rates: 1H Q1YTD FY2025 Forecasts : 1US$ = ¥145.00, 1RMB = ¥20.00 Forecasts Results % Revenue: Revenue 207.0 108.0 52.2 ・ORGOVYX® sales milestone
Slide 15: Research and Development
Research and Development © Sumitomo Pharma Co., Ltd. All Rights Reserved. 14
Slide 16: Development Pipeline (as of July 31, 2025)
Research and Development Development Pipeline (as of July 31, 2025) Revisions since the announcement in May 2025 are shown in red Area Generic name/Product code Mechanism of action, etc. Proposed indication Region Development stage Serotonin 5-HT2A receptor antagonist and serotonin 5- DSP-0038 Alzhe
Slide 17: Major Topics in Clinical Development
Research and Development Major Topics in Clinical Development Psychiatry & Neurology (Regenerative medicine/cell therapy) Allogeneic iPS cell-derived dopaminergic neural progenitor cells (Japan, collaboration with RACTHERA) • Parkinson’s disease （Japan） ・Preparing for NDA submission based on the
Slide 18: Oncology Area: nuvisertib Myelofibrosis
Research and Development Oncology Area: nuvisertib（TP-3654）Myelofibrosis（Oral presentation data at EHA 2025） Improvements in important efficacy measures were observed even in patients who did not respond to JAK inhibitors and in those with poor prognostic factors such as low hemoglobin and platele
Slide 19: Appendix Contents
＜Contents＞ Appendix P.19 Q1FY2025 P.20 Q1FY2025 Financial Results for Q1 FY2025 (Full Basis) Financial Position and Cash Flow P.21 Q1FY2025 GEMTESA® P.22 R&D Main Events/Targets for FY2025 P.23 R&D Product Launch Target P.24 R&D Regenerative Medicine/Cell Therapy Launched Product and Development Pip
Slide 20: Financial Results for Q1 FY2025 (Full Basis)
Appendix (Financial Results for Q1 FY2025) Financial Results for Q1 FY2025 (Full Basis) Billions of JPY Q1YTD Q1YTD Change FY2024 FY2025 Results Results Value ％ Revenue 90.7 108.0 17.3 19.1 Cost of sales 34.9 44.1 9.2 26.2 Gross profit 55.7 63.9 8.2 14.7 SG&A expenses 45.4 35.7 (9.7) (21.4) R&D expe
Slide 21: Financial Position and Cash Flow
Appendix (Financial Results for Q1 FY2025) Financial Position and Cash Flow Billions of JPY Ｂ/Ｓ As of March As of June Change 2025 2025 Assets 742.6 733.3 (9.3) Decrease due to FX rate impact Goodwill / Intangible assets 369.9 355.9 (14.0) Trade and other receivables 74.8 83.4 8.5 Assets held for sa
Slide 22: GEMTESA
Appendix (Financial Results for Q1 FY2025) GEMTESA® Despite the launch of Mirabegron generics in April 2024, the total number of GEMTESA® prescriptions and new prescriptions continued to increase. However, since January 2025, there was a slight decline due to changes in Medicare Part D coverage an
Slide 23: Main Events / Targets for FY2025
Appendix (Research and Development) Main Events / Targets for FY2025 (as of July 31, 2025) Allogeneic iPS cell-derived products (Parkinson’s disease): Obtain approval in Japan Allogeneic iPS cell-derived products (Parkinson’s disease): Advance Phase 1/2 study in the U.S. Psychiatry Allogeneic
Slide 24: Product Launch Target (as of July 31, 2025)
Appendix (Research and Development) Psychiatry & Product Launch Target (as of July 31, 2025) Neurology Oncology Others Revisions since the announcement in May 2025 are shown in red FY2025 2026 2027 2028 2029 Allogeneic iPS cell-derived dopaminergic neural progenitor Parkinson’s disease Development c
Slide 25: Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline
Appendix (Research and Development) Regenerative Medicine/Cell Therapy Launched Product and Development Pipeline(RACTHERA Co., Ltd.) (as of July 31, 2025) Brand name/Cell type JP/ Clinical Approval Approval→ Indications Pre-clinical Phase 1/2 Phase 3 Product code US research application Launch RETHY
Slide 26: Sumitomo Pharma
< Sumitomo Pharma Innovation today, healthier tomorrows